Project Grant R21TR005163
Award Date
8/15/24
Completion Date
7/31/26
Dollars Obligated
$431K
Federal Agency
National Center for Advancing Translational Sciences
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Durham, NC 27701, USA
Similar Awards
This Project Grant award of $803,132 from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) will support research to identify biomarkers that can guide enrollment criteria and assess efficacy for future clinical trials of novel therapies for LCAT deficiency, an ultra-rare genetic disorder. The research aims to: 1) identify diagnostic and prognostic biomarkers to distinguish between the two LCAT deficiency syndromes and enrich for patients at higher risk of disease...
This $156,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) supports research to develop a novel murine model of 2-hydroxyglutaric aciduria, a rare metabolic disorder. The awardee, Georgetown University, will use this funding from Sep 2024 to Aug 2026 to identify the pathways by which the two enantiomeric forms of 2-hydroxyglutaric acid are produced in the context of SLC25A1 gene mutations, and assess how these compounds affect embryonic...
This federal Project Grant award of $249,000 from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) aims to identify new therapeutics and understand molecular mechanisms for Congenital Disorders of Glycosylation (CDGs). The key objectives are to: 1) Determine the mechanisms of modifier genes that can rescue a DPAGT1-CDG cell model, 2) Conduct a drug repurposing screen in a DPAGT1-CDG...
This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for the compound N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives of this Phase I STTR study are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model of...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) provides $594,547 to the University of California, Davis to develop and characterize an orally delivered nanodrug designed to compensate for the shortage of specific microbial metabolite-regulated signaling in liver and colon cancer patients. The nanodrug, named PRORA, combines a histone deacetylase...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $808,866 to Progenra Inc., a biotechnology firm located in Malvern, Pennsylvania. The funding supports research to evaluate novel small molecule compounds that activate the ubiquitin proteasome system (UPS) as potential therapeutics for treating acute and chronic pancreatitis. Key objectives include assessing...
This federal Project Grant award of $255,343 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) will fund a study investigating the impact of phenylalanine elevations on metabolic, cognitive, and neural functioning in adults heterozygous for phenylketonuria (PKU). The study will conduct a double-blind crossover experiment to assess the acute effects of...
This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, will support research to define the impact of the histone methyltransferase MET-2 on mitochondria morphology, function, and protein abundance in C. elegans. The $155,559 award, granted on June 17, 2025, will enable the University of Delaware to generate new genome-edited strains, utilize advanced imaging techniques, and perform quantitative proteomics analysis to better understand...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $762,974 in funding to Duke University to conduct research on alveolar injury and repair in Pompe disease. The key objectives are to: Determine if GAA-deficient alveolar type 2 cells can successfully differentiate, repair, and repopulate damaged alveolar cells following lung injury in a Pompe disease mouse model. Elucidate the impact of GAA...
This $101,925 Project Grant award was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) to investigate the role of the propionate metabolism pathway in the aging process. The 2-year project aims to: Continue studying the impact of methylmalonic acid (MMA), a metabolite in the propionate pathway, on cell senescence and aging-associated pulmonary fibrosis. Characterize a novel function of propionyl-CoA (P-CoA), another pathway...